42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd bought a new stake of 42,283 shares of IDEAYA Biosciences (NASDAQ:IDYA) in Q3, valued at about $1.15 million, and institutional investors now own roughly 98.29% of the stock.
• Director Jeffrey Stein purchased 50,000 shares on March 2 at an average price of $32.96 (≈$1.65 million), increasing his holdings to 54,281 shares; insiders hold about 2.5% of the company.
• IDEAYA beat estimates with quarterly EPS of −$0.94 (vs. −$1.03 expected) and revenue of $21.75M (vs. $5.95M expected), while Wall Street's consensus is a Moderate Buy with an average target of $48.69.

WINTON GROUP Ltd bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,283 shares of the company's stock, valued at approximately $1,151,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. General American Investors Co. Inc. lifted its stake in IDEAYA Biosciences by 7.7% during the third quarter. General American Investors Co. Inc. now owns 280,261 shares of the company's stock worth $7,626,000 after purchasing an additional 20,000 shares during the last quarter. Candriam S.C.A. raised its holdings in IDEAYA Biosciences by 10.8% during the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company's stock worth $27,563,000 after purchasing an additional 98,567 shares in the last quarter. Knights of Columbus Asset Advisors LLC purchased a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $934,000. Envestnet Asset Management Inc. lifted its position in shares of IDEAYA Biosciences by 174.0% during the 3rd quarter. Envestnet Asset Management Inc. now owns 299,032 shares of the company's stock worth $8,137,000 after buying an additional 189,877 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in shares of IDEAYA Biosciences by 26.5% in the 3rd quarter. Aberdeen Group plc now owns 558,048 shares of the company's stock valued at $15,184,000 after buying an additional 116,743 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Performance

Shares of IDYA opened at $34.05 on Thursday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $39.28. The firm has a 50-day simple moving average of $33.85 and a 200-day simple moving average of $31.40. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of -25.99 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.09. The company had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. The business's revenue was up 55.7% on a year-over-year basis. During the same quarter last year, the firm earned ($1.49) EPS. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IDYA. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $49.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Truist Financial upped their price objective on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, January 6th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. UBS Group began coverage on IDEAYA Biosciences in a research note on Wednesday, January 7th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $48.69.

Insider Activity

In related news, Director Jeffrey Stein bought 50,000 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were acquired at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This trade represents a 1,167.95% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.50% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.